Abbott India Ltd non-exclusive patent license agreement with Takeda for Vonoprazan

Abbott India Limited (hereafter referred to as "Abbott") has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company Limited (hereafter referred to as "Takeda") to market and distribute "Vonoprazan" in India under the brand name "Vonefi".

Vonoprazan (PCAB or Potassium Competitive Acid Blocker) addresses severe acid related disorders like reflux esophagitis through a once daily dose. Current treatments for reflux esophagitis, a condition under the Gastroesophageal Reflux Disease (GERD) umbrella, have several limitations including the need for multiple dosing for effectiveness, especially when the condition is severe. Vonoprazan, a first-of-its kind therapy, will help make it easier for patients to comply with their treatment and manage their condition better.

This license will enable Abbott, a leader in the gut health space, to enhance access to this novel therapy to more patients across India.

Shares of Abbott India Limited was last trading in BSE at Rs. 27963.25 as compared to the previous close of Rs. 27795.60. The total number of shares traded during the day was 797 in over 592 trades.

The stock hit an intraday high of Rs. 28176.45 and intraday low of 27576.10. The net turnover during the day was Rs. 22258600.00.

Source : Equity Bulls

Keywords

AbbottIndia INE358A01014 Pharmaceuticals NonExclusive PatentLicenseAgreement Takeda Vonoprazan Vonefi India